EVALUATION OF THE BRONCHOPROTECTIVE EFFECT OF ARFORMOTEROL IN CHILDREN WITH
阿福特罗对患有以下疾病的儿童的支气管保护作用的评估
基本信息
- 批准号:7952082
- 负责人:
- 金额:$ 1.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-12-01 至 2009-11-30
- 项目状态:已结题
- 来源:
- 关键词:5 year oldAdultAsthmaBreathingBronchoconstrictionChemicalsChildChronic Obstructive Airway DiseaseClinical ResearchComputer Retrieval of Information on Scientific Projects DatabaseDevicesEvaluationExercise-Induced BronchospasmFDA approvedFundingGrantHandImageInhalatorsInstitutionLeftMaintenanceNew MexicoPatientsPharmaceutical PreparationsPhase III Clinical TrialsPlacebosPowder dose formPreventionResearchResearch PersonnelResourcesSolutionsSourceUnited States National Institutes of HealthUniversitiesWorkformoterolpreventyoung adult
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
This research is studying the use of arformoterol for exercise induced bronchospasm [EIB]. In this study we compare arformoterol inhalation solution to formoterol dry powder inhaler, and placebo [no active drug].
EIB is common in children and young adults and it can be prevented by using medications. Formoterol in a dry powder inhaler device has been approved by the FDA to be used in the maintenance [daily] treatment of asthma and in the prevention of EIB in adults and children 5 years of age and older. Formoterol is made of two chemical compounds: The best way to explain this is to think of these two chemical compounds as your hands. Formoterol is both the left and right hand, mirror images, pressed together but only the right hand is active [R,R-formoterol], and the left hand [called S,S-formoterol] is there keeping it company. R,R-formoterol is also called arformoterol. Arformoterol inhalation solution is approved by the FDA for maintenance treatment of bronchoconstriction in adult patients with chronic obstructive pulmonary disease [COPD]. We would like to know if arformoterol inhalation will work for the prevention of EIB. This is a Phase III study of arformoterol in children with EIB, meaning that the use of arformoterol for EIB is experimental.
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
本研究正在研究阿福特罗治疗运动诱发支气管痉挛[EIB]。在这项研究中,我们比较了阿福特罗吸入溶液、福莫特罗干粉吸入剂和安慰剂[无活性药物]。
EIB在儿童和年轻人中很常见,可以通过药物预防。福莫特罗干粉吸入器装置已被FDA批准用于成人和5岁及以上儿童哮喘的维持[每日]治疗和EIB的预防。福莫特罗由两种化合物组成:解释这一点的最佳方法是将这两种化合物想象为你的手。 福莫特罗是左手和右手的镜像,压在一起,但只有右手是活动的[R,R-福莫特罗],而左手[称为S,S-福莫特罗]在那里陪伴它。 R,R-福莫特罗也称为阿福特罗。阿福特罗吸入溶液经FDA批准用于慢性阻塞性肺疾病[COPD]成人患者支气管收缩的维持治疗。我们想知道吸入阿福特罗是否对预防EIB有效。这是一项在EIB儿童中进行的阿福特罗III期研究,这意味着阿福特罗用于EIB是实验性的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HENGAMEH RAISSY其他文献
HENGAMEH RAISSY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HENGAMEH RAISSY', 18)}}的其他基金
TREATING CHILDREN TO PREVENT EXACERBATIONS OF ASTHMA (TREXA)
治疗儿童预防哮喘恶化 (TREXA)
- 批准号:
8166624 - 财政年份:2009
- 资助金额:
$ 1.79万 - 项目类别:
MAINTENANCE VS INTERMITTENT INHALED STEROIDS IN WHEEZING TODDLERS (MIST)
喘息幼儿的维持与间歇性吸入类固醇(雾)
- 批准号:
8166632 - 财政年份:2009
- 资助金额:
$ 1.79万 - 项目类别:
EVALUATION OF THE BRONCHOPROTECTIVE EFFECT OF ARFORMOTEROL IN CHILDREN WITH
阿福特罗对患有以下疾病的儿童的支气管保护作用的评估
- 批准号:
8166621 - 财政年份:2009
- 资助金额:
$ 1.79万 - 项目类别:
PRETREATMENT WITH ALBUTEROL VS MONTELUKAST IN EXERCISE INDUCED BRONCHOSPASM IN
沙丁胺醇与孟鲁司特预处理在运动诱发的支气管痉挛中的比较
- 批准号:
7716587 - 财政年份:2008
- 资助金额:
$ 1.79万 - 项目类别:
TREATING CHILDREN TO PREVENT EXACERBATIONS OF ASTHMA (TREXA)
治疗儿童预防哮喘恶化 (TREXA)
- 批准号:
7952085 - 财政年份:2008
- 资助金额:
$ 1.79万 - 项目类别:
PRETREATMENT WITH ALBUTEROL VS MONTELUKAST IN EXERCISE INDUCED BRONCHOSPASM IN
沙丁胺醇与孟鲁司特预处理在运动诱发的支气管痉挛中的比较
- 批准号:
7606898 - 财政年份:2006
- 资助金额:
$ 1.79万 - 项目类别:
相似海外基金
A novel patient-facing mobile platform to collect and implement patient-reported outcomes and voice biomarkers in underserved adult patients with asthma
一种面向患者的新型移动平台,用于收集和实施服务不足的成年哮喘患者的患者报告结果和语音生物标志物
- 批准号:
10665856 - 财政年份:2023
- 资助金额:
$ 1.79万 - 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
- 批准号:
10398799 - 财政年份:2021
- 资助金额:
$ 1.79万 - 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
- 批准号:
10609049 - 财政年份:2021
- 资助金额:
$ 1.79万 - 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
- 批准号:
10084583 - 财政年份:2021
- 资助金额:
$ 1.79万 - 项目类别:
Development of nurse-led support to enhance self-management in adult-onset asthma patients
开发护士主导的支持以加强成人哮喘患者的自我管理
- 批准号:
20K23142 - 财政年份:2020
- 资助金额:
$ 1.79万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
CC16 in Childhood and Resilience to Persistent Asthma into Adult Life (Supplement)
CC16 在童年和成年生活中对持续性哮喘的抵抗力(补充)
- 批准号:
10189106 - 财政年份:2020
- 资助金额:
$ 1.79万 - 项目类别:
Investigating the Social Determinant and Developmental Risk Patterns in Childhood and Adolescence Associated with Adult Asthma and Diabetes Onset
调查儿童期和青少年期与成人哮喘和糖尿病发病相关的社会决定因素和发育风险模式
- 批准号:
450250 - 财政年份:2020
- 资助金额:
$ 1.79万 - 项目类别:
Studentship Programs
Immunometabolic phenotypes in adult severe asthma and disease progression
成人严重哮喘和疾病进展的免疫代谢表型
- 批准号:
10896787 - 财政年份:2019
- 资助金额:
$ 1.79万 - 项目类别:
Immunometabolic phenotypes in adult severe asthma and disease progression
成人严重哮喘和疾病进展的免疫代谢表型
- 批准号:
10022504 - 财政年份:2019
- 资助金额:
$ 1.79万 - 项目类别:
Immunometabolic phenotypes in adult severe asthma and disease progression
成人严重哮喘和疾病进展的免疫代谢表型
- 批准号:
10684256 - 财政年份:2019
- 资助金额:
$ 1.79万 - 项目类别: